Meaterm LogoMeaterm LogoMeaterm
Stock research

Cencora, Inc. (COR) stock

Industrials·Wholesale-Drugs, Proprietaries & Druggists' Sundries·Market cap $61.8B
Auto-Brief · synthesised from 5 layers
COR · us_stock
NEUTRAL
Top reasons
  1. 1earnings: COR Q4 2026 earnings scheduled (scheduled 2026-11-04)
  2. 2Revenue growth 5.1% YoY, net margin 0.8%.
Generated 2026-10-13 05:59 UTC5 layers
Meaterm briefs are analytical research. Not investment advice. Not a recommendation to buy, sell, or hold any asset.

Factor grades

As of 2026-10-12
Meaterm Score
C
52nd percentile
Valuation
C-
43rd percentile
Growth
B-
62nd percentile
Profitability
C+
55th percentile
Momentum
C
47th percentile

Percentile grades within the stock’s sector, computed nightly from SEC filings. Statistical ranking, not investment advice.

Fair value estimate

Fair value estimate
—

No estimate: fewer than three companies in the same industry are within ten times this company’s size, too few to take a median from.

Research COR with the full toolkit
Charts, screeners, factor rankings, filings and positioning data in one browser-based terminal. Free tier, no card required.
Open COR in the Meaterm terminal →
MacroNEUTRALNo feed
0 items
  • No macro events in the recency window.
No macro events in the recency window.
CatalystsNEUTRALLive
1 item
  • earnings: COR Q4 2026 earnings scheduled (scheduled 2026-11-04)
  1. earningsScheduled 2026-11-04
    COR Q4 2026 earnings scheduled
    Consensus EPS 4.62.
    NEUTRAL
FundamentalsNEUTRALLive
1 item
  • Revenue growth 5.1% YoY, net margin 0.8%.
  • Forward P/E —, FCF $3.6B.
Revenue growth (YoY)
5.1%
>10% strong
Net margin
0.8%
>15% healthy
Debt / Equity
3.84
<1 conservative
Interest coverage
—
Beta
—
Forward P/E
—
Free cash flow
$3.6B
TTM
Earnings beat rate
—
As of 2026-06-30 · Issuer filings + market data
PositioningNEUTRALNo feed
0 items
  • Peers: 151 of 240 recently-briefed us stock names lean bullish.
As of 2026-10-13 · Meaterm
NewsNEUTRALNo feed
0 items
  • No news in the recency window.
  • Signal steady (neutral) vs the last brief.
No news in the recency window.

Key fundamentals

Revenue (TTM)
$332.8B
Net income (TTM)
$2.6B
Diluted EPS (TTM)
$13.47
Gross margin
4.0%
Operating margin
0.9%
Net margin
0.8%

Trailing-twelve-month figures computed by Meaterm from SEC filings, refreshed nightly.

Related Wholesale-Drugs, Proprietaries & Druggists' Sundries stocks

MCKMCKESSON CORPCAHCARDINAL HEALTH INCHLFHERBALIFE LTD.WGRXWellgistics Health, Inc.MEDSDataMeds AI, Inc.

Frequently asked questions

What are the COR factor grades?

Meaterm scores Cencora, Inc. (COR) on four factors — valuation, growth, profitability and momentum — plus an overall Meaterm Score. Each grade is a percentile ranking against the stock's sector, computed nightly from SEC-filed financial data. Grades are statistical rankings, not investment advice or a recommendation to trade.

How is the fair value estimate for COR calculated?

The estimate is the median of several peer-multiple implied values — peer P/E, EV/EBITDA, P/S and P/B applied to the company's own fundamentals — plus a sell-side consensus target when one is available. Peers come from the same industry, matched by size. When the company’s own size is not on record, or the comparable companies are too few, more than ten times larger or smaller, or disagree too much with each other or with the market price, no estimate is published and the page says why. It is a statistical reference point, not a price target and not investment advice.

Where does the data on this page come from?

Fundamentals and factor grades are computed by Meaterm from SEC filings and refreshed nightly. Positioning context comes from public CFTC and FINRA releases, and macro series from FRED. Every signal, grade and estimate shown is Meaterm’s own computation.

Is COR a good stock to invest in?

Meaterm does not answer that question. This page shows how Cencora, Inc. (COR) ranks statistically against sector peers on valuation, growth, profitability and momentum and, where its peer group supports one, where its price sits relative to a peer-multiple estimate. Use it as research context alongside your own analysis — nothing on this page is investment advice.

How often is this page updated?

Factor grades, fundamentals and the company profile refresh nightly after each trading day. The brief layers — macro, catalysts, positioning and news — are composed when the page loads, and the fair value estimate is recomputed with recent quotes during the day.